NASDAQ:PNT

POINT Biopharma Global (PNT) Stock Forecast, Price & News

$9.41

+0.02 (+0.21%)

(As of 05/26/2023 04:00 PM ET)

Compare

Today's Range: $9.26
▼
$9.65
50-Day Range: $6.78
▼
$10.86
52-Week Range: $5.59
▼
$11.13

Volume: 458,900 shs
Average Volume: 630,465 shs
Market Capitalization: $994.45 million

P/E Ratio: 11.20
Dividend Yield: N/A
Price Target: $15.71

POINT Biopharma Global MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 67.0% Upside
$15.71 Price Target
Short Interest: Bearish
9.85% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.76) to ($0.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

341st out of 1,010 stocks

Pharmaceutical Preparations Industry

151st out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
POINT Biopharma Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.71, POINT Biopharma Global has a forecasted upside of 67.0% from its current price of $9.41.
Amount of Analyst Coverage
POINT Biopharma Global has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.85% of the float of POINT Biopharma Global has been sold short.
Short Interest Ratio / Days to Cover
POINT Biopharma Global has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
Change versus previous month
Short interest in POINT Biopharma Global has recently decreased by 1.40%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
POINT Biopharma Global does not currently pay a dividend.
Dividend Growth
POINT Biopharma Global does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PNT.

2.7

News and Social Media Coverage

News Sentiment
POINT Biopharma Global has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for POINT Biopharma Global this week, compared to 3 articles on an average week.
Search Interest
Only 9 people have searched for PNT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
6 people have added POINT Biopharma Global to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, POINT Biopharma Global insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.70% of the stock of POINT Biopharma Global is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.77% of the stock of POINT Biopharma Global is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for POINT Biopharma Global are expected to grow in the coming year, from ($0.76) to ($0.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of POINT Biopharma Global is 11.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.94.
Price to Earnings Ratio vs. Sector
The P/E ratio of POINT Biopharma Global is 11.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 96.12.
Price to Book Value per Share Ratio
POINT Biopharma Global has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About POINT Biopharma Global (NASDAQ:PNT) Stock

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Stock News Headlines

May 25, 2023 | finance.yahoo.com

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

May 20, 2023 | americanbankingnews.com

FY2023 EPS Estimates for POINT Biopharma Global Inc. (NASDAQ:PNT) Boosted by Analyst

May 29, 2023 | Behind the Markets (Ad)

Why Your IRA Could Crash on June 16th

China will attack Taiwan as soon as June 16th, 2023. The stock market will crash at least 35% when China makes their move.

May 19, 2023 | seekingalpha.com

POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials

May 17, 2023 | americanbankingnews.com

POINT Biopharma Global Inc. Forecasted to Post Q1 2024 Earnings of ($0.29) Per Share (NASDAQ:PNT)

May 17, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for POINT Biopharma Global Inc. (NASDAQ:PNT) Boosted by Analyst

May 17, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: POINT Biopharma Global (PNT), NewAmsterdam Pharma Company (NAMS)

May 16, 2023 | msn.com

Oppenheimer Reiterates POINT Biopharma Global (PNT) Outperform Recommendation

May 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 15, 2023 | msn.com

Why Shares of Point Biopharma Global Rose Monday

May 15, 2023 | finance.yahoo.com

POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 15, 2023 | finance.yahoo.com

POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer

May 14, 2023 | investing.com

POINT Biopharma Global (PNT) Earnings Dates & Reports

May 13, 2023 | americanbankingnews.com

Brokerages Set POINT Biopharma Global Inc. (NASDAQ:PNT) Target Price at $16.25

May 10, 2023 | finance.yahoo.com

Are Investors Undervaluing POINT Biopharma Global Inc. (NASDAQ:PNT) By 46%?

April 24, 2023 | marketwatch.com

Lantheus, POINT Biopharma Granted FDA Fast Track Designation for Lu-PNT2002 Prostate Cancer Drug

April 24, 2023 | finance.yahoo.com

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

April 20, 2023 | finance.yahoo.com

Taking A Look At POINT Biopharma Global Inc.'s (NASDAQ:PNT) ROE

April 18, 2023 | americanbankingnews.com

Analysts Set POINT Biopharma Global Inc. (NASDAQ:PNT) PT at $16.25

April 12, 2023 | americanbankingnews.com

POINT Biopharma Global (NASDAQ:PNT) Shares Down 3.4%

April 4, 2023 | finance.yahoo.com

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

April 1, 2023 | americanbankingnews.com

POINT Biopharma Global Inc. Expected to Post Q1 2023 Earnings of ($0.35) Per Share (NASDAQ:PNT)

April 1, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for POINT Biopharma Global Inc. Decreased by Analyst (NASDAQ:PNT)

March 31, 2023 | americanbankingnews.com

POINT Biopharma Global (NASDAQ:PNT) Trading 6.6% Higher

March 31, 2023 | americanbankingnews.com

POINT Biopharma Global Inc. Forecasted to Post FY2027 Earnings of $0.21 Per Share (NASDAQ:PNT)

March 31, 2023 | americanbankingnews.com

Oppenheimer Comments on POINT Biopharma Global Inc.'s FY2027 Earnings (NASDAQ:PNT)

March 30, 2023 | americanbankingnews.com

William Blair Weighs in on POINT Biopharma Global Inc.'s Q1 2023 Earnings (NASDAQ:PNT)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter.

PNT Company Calendar

Last Earnings: 3/27/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PNT
CUSIP: N/A
CIK: 1811764
Web: www.pointbiopharma.com
Phone: 64-7812-2417
Fax: N/A
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.71
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +67.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.84
Trailing P/E Ratio: 11.20
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $98.29 million
Net Margins: N/A
Pretax Margin: 54.70%
Return on Equity: 26.47%
Return on Assets: 23.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.58
Quick Ratio: 5.58

Sales & Book Value

Annual Sales: $226.58 million
Price / Sales: 4.39
Cash Flow: $0.94 per share
Price / Cash Flow: 10.02
Book Value: $4.68 per share
Price / Book: 2.01

Miscellaneous

Outstanding Shares: 105,680,000
Free Float: 85,920,000
Market Cap: $994.45 million
Optionable: Not Optionable
Beta: 0.14

Key Executives

Mr. Allan Charles Silber (Age 72)
Exec. Chairman
Comp: $677.8k

Dr. Joe A. McCann Ph.D. (Age 44)
CEO & Director
Comp: $740.31k

Dr. Neil E. Fleshner FRCSC (Age 59)
M.D., M.PH, Chief Medical Officer & Director
Comp: $227.5k

Ms. Jessica D. Jensen M.P.H. (Age 41)
MPH, Exec. VP of Clinical Devel.
Comp: $541.59k

Mr. Bill Demers B.B.A. (Age 64)
F.C.A., FCPA, Chief Financial Officer

Ms. Justyna Kelly M.Sc. (Age 37)
Chief Operating Officer

Ms. Donna Husack B.A.
VP of HR

Mr. Ari Shomair
VP of Corp. Affairs & Chief of Staff

Dr. Myra Rosario Herle Ph.D.
R.Ph., Exec. VP of Regulatory Affairs

Dr. Matthew P. Vincent J.D.
Ph.D., Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PNT Stock - Frequently Asked Questions

Should I buy or sell POINT Biopharma Global stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PNT shares.
View PNT analyst ratings or view top-rated stocks.
What is POINT Biopharma Global's stock price forecast for 2023?: 8 Wall Street analysts have issued 12-month price objectives for POINT Biopharma Global's stock. Their PNT share price forecasts range from $11.00 to $22.00. On average, they anticipate the company's stock price to reach $15.71 in the next twelve months. This suggests a possible upside of 67.0% from the stock's current price.
View analysts price targets for PNT or view top-rated stocks among Wall Street analysts.
How have PNT shares performed in 2023?: POINT Biopharma Global's stock was trading at $7.29 at the beginning of 2023. Since then, PNT stock has increased by 29.1% and is now trading at $9.41.
View the best growth stocks for 2023 here.
When is POINT Biopharma Global's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our PNT earnings forecast.
How were POINT Biopharma Global's earnings last quarter?: POINT Biopharma Global Inc. (NASDAQ:PNT) issued its earnings results on Monday, March, 27th. The company reported $1.53 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $1.79. The company earned $226.58 million during the quarter, compared to the consensus estimate of $260 million.
What ETFs hold POINT Biopharma Global's stock?: ETFs with the largest weight of POINT Biopharma Global (NASDAQ:PNT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and iShares Micro-Cap ETF (IWC).Direxion Daily S&P Biotech Bull 3x Shares (LABU),

What is POINT Biopharma Global's stock symbol?: POINT Biopharma Global trades on the NASDAQ under the ticker symbol "PNT."
Who are POINT Biopharma Global's major shareholders?: POINT Biopharma Global's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (10.00%), BlackRock Inc. (5.19%), Great Point Partners LLC (3.20%), State Street Corp (2.95%), Rubric Capital Management LP (2.50%) and Geode Capital Management LLC (1.50%). Insiders that own company stock include Allan C Silber, Joe A Mccann, Jonathan R Goodman, Neil E Fleshner and Yael Margolin.
View institutional ownership trends.
How do I buy shares of POINT Biopharma Global?: Shares of PNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is POINT Biopharma Global's stock price today?: One share of PNT stock can currently be purchased for approximately $9.41.
How much money does POINT Biopharma Global make?: POINT Biopharma Global (NASDAQ:PNT) has a market capitalization of $994.45 million and generates $226.58 million in revenue each year. The company earns $98.29 million in net income (profit) each year or $0.84 on an earnings per share basis.
How can I contact POINT Biopharma Global?: POINT Biopharma Global's mailing address is 200 BERKELEY STREET 18TH FLOOR, BOSTON MA, 02116. The official website for the company is www.pointbiopharma.com. The company can be reached via phone at 64-7812-2417.

This page (NASDAQ:PNT) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

POINT Biopharma Global (PNT) Stock Forecast, Price & News

POINT Biopharma Global MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About POINT Biopharma Global (NASDAQ:PNT) Stock

PNT Stock News Headlines

PNT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PNT Stock - Frequently Asked Questions

Overall MarketRank^™